The Centers for Medicare & Medicaid Services (CMS) has granted a transitional pass-through status C-Code for MiMedx Group's EpiFix Amniotic Membrane Allograft.
The status has been given under Medicare’s outpatient prospective payment system (OPPS) which will be effective from 1 January 2012.
The code will cover the grafts used in treating Medicare patients with dermal wounds in the hospital operating room or a freestanding surgical suite.
Medx Groupchairman and CEO Parker Petit said by making EpiFix eligible for coverage and reimbursement for the Medicare beneficiaries and these individuals will be able to receive the benefits of this treatment for wounds.